Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
67 studies found for:    Open Studies | "Eye Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Eye Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting MRI in Diagnosing Solid Tumors of the Eye and Orbit
Condition: Eye Cancer
Intervention: Procedure: dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
2 Recruiting Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid
Condition: Eye Cancer
Interventions: Procedure: Lymphatic Mapping;   Procedure: SLN Mapping/Biopsy
3 Recruiting The Role of Inflammation in Ocular Tumours
Condition: Ocular Melanoma
Intervention: Other: cSLO imaging
4 Recruiting Postoperative Pain in Orbital Disease and Ocular Tumor
Condition: Postoperative Pain
Intervention: Procedure: general anesthesia,orbital operation
5 Not yet recruiting Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract
Interventions: Drug: Lenvatinib;   Drug: Capecitabine
6 Recruiting Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma
Conditions: Malignant Neoplasms, Eye;   Glioblastoma;   Malignant Neoplasms, Brain;   Malignant Neoplasms, Central Nervous System
Interventions: Drug: FDG;   Procedure: PET/CT;   Procedure: MRI
7 Recruiting MRI and Orbital Tumours (MEDORT)
Conditions: Orbital Tumor;   Orbital Pseudotumor
Intervention: Other: MRI
8 Not yet recruiting Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma
Condition: Hemodynamic Instability
Interventions: Drug: Tetracaine 0.5%;   Drug: Lidocaine hydrochloride ophthalmic gel 3.5%
9 Recruiting Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Condition: Uveal Melanoma
Interventions: Procedure: SIRT;   Procedure: DSM-TACE
10 Not yet recruiting G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Neuroblastoma;   Hepatoblastoma;   Retinoblastoma
Interventions: Biological: GM-CSF;   Biological: G-CSF;   Biological: GM-CSF and G-CSF
11 Not yet recruiting Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Conditions: Uveal Melanoma;   Hepatic Metastases
Interventions: Device: SIR-Spheres® Yttrium 90;   Drug: ipilimumab;   Drug: nivolumab
12 Recruiting Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)
Conditions: Uveal Melanoma;   Melanoma, Uveal
Interventions: Procedure: Endoresection;   Procedure: Laser diode
13 Recruiting Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)
Condition: Retinoblastoma
Interventions: Other: Observation;   Drug: Etoposide;   Drug: Vincristine;   Radiation: Orbital irradiation;   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Procedure: Cytapheresis;   Procedure: Peripheral bood stem cell transplantation
14 Recruiting Conservative Treatments of Retinoblastoma
Conditions: Retinoblastoma;   Children;   Retinal Neoplasm
Interventions: Drug: VP16, carboplatin;   Drug: Melphalan;   Drug: VP16, carboplatin, vincristin;   Drug: Carboplatin + laser day 1 (chemothermotherapy);   Device: Laser (local treatment);   Device: cryoapplication (local treatment);   Radiation: I125 radioactive plaques (local treatment);   Drug: intravitreal Melphalan (local treatment)
15 Recruiting Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Condition: Uveal Melanoma
Intervention: Biological: Blood sampling
16 Recruiting Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Conditions: Neuroblastoma;   Sarcoma;   Carcinoma;   Desmoplastic Small Round Cell Tumor;   Retinoblastoma;   Wilms Tumor;   Melanoma;   Germ Cell Tumor;   Hepatoblastoma
Intervention:
17 Recruiting Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: Adjuvant chemotherapy by Fotemustin;   Other: Intensive surveillance
18 Recruiting Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma
Condition: Retinoblastoma
Interventions: Drug: Carboplatin;   Drug: Maxitrol®;   Procedure: Focal Therapy;   Procedure: Plaque Radiotherapy
19 Recruiting Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Conditions: Uveal Melanoma;   Choroid Neoplasm
Intervention: Biological: ICON-1
20 Not yet recruiting Intermittent Selumetinib for Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: Selumetinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.